Our lead program and current focus is on the development of the fixed dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor ...

Vosevi can also be used to treat genotype 1a or 3 patients who previously received sofosbuvir without an NS5A inhibitor over a 12 week period. But the new launch isn't expected to reverse the ...

Treatment-naive: treat for 8 weeks. Treatment-experienced (genotype 1): treat for 16 weeks if previously treated with an NS5A inhibitor (without prior NS3/4A protease inhibitor) or for 12 weeks if ...